Evidence map›Paper›PMID 30651113›Full record

ArticleCell communication and signaling : CCS2019

Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of K

Theresa Lowinus, Florian H Heidel, Tanima Bose, Subbaiah Chary Nimmagadda, Tina Schnöder, Clemens Cammann, Ingo Schmitz, Ulrike Seifert, Thomas Fischer, Burkhart Schraven and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Altered expression and functional role of ion channels in leukemia: bench to bedside.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Theresa LowinusInstitute of Molecular and Clinical Immunology, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Florian H HeidelDepartment of Hematology and Oncology, GC-I3, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.
Tanima BoseLeibniz Institute of Neurobiology, Magdeburg, Germany.
Subbaiah Chary NimmagaddaDepartment of Hematology and Oncology, GC-I3, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.
Tina SchnöderDepartment of Hematology and Oncology, GC-I3, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.
Clemens CammannFriedrich Loeffler Institute for Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
Ingo SchmitzInstitute of Molecular and Clinical Immunology, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Ulrike SeifertInstitute of Molecular and Clinical Immunology, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Thomas FischerDepartment of Hematology and Oncology, GC-I3, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.
Burkhart SchravenInstitute of Molecular and Clinical Immunology, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Ursula BommhardtInstitute of Molecular and Clinical Immunology, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. Ursula.Bommhardt@med.ovgu.de.
Otto-von-Guericke University Magdeburg · DEFriedrich-Loeffler-Institut · DELeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DEHelmholtz Centre for Infection Research · DEInstitute of Neuroimmunology of the Slovak Academy of Sciences · SKUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of acute leukemia is challenging and long-lasting remissions are difficult to induce. Innovative therapy approaches aim to complement standard chemotherapy to improve drug efficacy and decrease toxicity. Promising new therapeutic targets in cancer therapy include voltage-gated K

methodsWe analyzed acute lymphoid (Jurkat, CEM) and myeloid (HL-60, Molm-13, OCI-AML-3) leukemia cell lines and patients' acute leukemic blasts after treatment with either drug alone or the combination of cytarabine and memantine. Patch-clamp analysis was performed to evaluate inhibition of K

resultsOur study demonstrates that memantine inhibits K

conclusionsOur study underlines inhibition of K

Indexed as

Adenosine TriphosphateApoptosisCaspase 3Cell Line, TumorCell ProliferationCytarabineCytochromes cHumansKv1.3 Potassium ChannelLeukemia, Myeloid, AcuteMAP Kinase Signaling SystemMemantineProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycAdenosine TriphosphateCaspase 3CytarabineCytochromes cKv1.3 Potassium ChannelMemantineProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycAcute leukemiaCell deathCytarabineMemantineSignaling

Identifiers

PMID30651113
PMCPMC6335768
OpenAlexW2941261613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.